A program to convert patients from trade-name to generic clozapine

Pharmacotherapy

Volumn 23, Issue 6, 2003, Pages 806-810

  Stoner, Steven C ^a,b   Lea, Jessica W ^a,b   Dubisar, Beth ^a,b   Marken, Patricia A ^a   Ramlatchman, Leonard V ^b   Reynolds, James ^b  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b Northwest Missouri Psychiatric Rehabilitation Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; GENERIC DRUG;

ABDOMINAL DISCOMFORT; ADULT; ARTICLE; BIOEQUIVALENCE; CLINICAL ARTICLE; CONSTIPATION; DRUG EFFICACY; DRUG PROGRAM; DRUG RESPONSE; DRUG TOLERABILITY; HOSPITAL PATIENT; HOSPITAL PHARMACY; HUMAN; HYPERSALIVATION; LEUKOCYTE COUNT; LUNG EMBOLISM; MENTAL HOSPITAL; MENTAL PATIENT; NEUTROPENIA; NEUTROPHIL; PSYCHOPHARMACOTHERAPY; RATING SCALE; SCORING SYSTEM; SEDATION; SIDE EFFECT; STATISTICAL SIGNIFICANCE; UNITED STATES;

ADULT; ANTIPSYCHOTIC AGENTS; BRIEF PSYCHIATRIC RATING SCALE; CLOZAPINE; DRUGS, GENERIC; HUMANS; SCHIZOPHRENIA; THERAPEUTIC EQUIVALENCY; TREATMENT OUTCOME;

EID: 0037674749     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.23.6.806.32183     Document Type: Article

References (14)

1. Essock SM, Frisman LK, Covell NH, Hargreaves WA. Cost-effectiveness of clozapine compared with conventional antipsychotic medication for patients in state hospitals. Arch Gen Psychiatry 2000;57:987-94.
2. Rosenheck R, Cramer J, Weichun X, et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. N Engl J Med 1997;337:809-15.
3. McEvoy JP, Scheifler PL, Frances A, eds. Expert consensus guideline series: treatment of schizophrenia 1999. J Clin Psychiatry 1999;60(11):1-80.
4. Lam YWF, Ereshefsky L, Toney GB, Gonzales C. Branded versus generic clozapine: bioavailability comparison and interchangeability issues. J Clin Psychiatry 2001;62(suppl 5):18-22.
5. Ereshefsky L, Glazer WM. Comparison of the bioequivalence of generic versus branded clozapine. J Clin Psychiatry 2001;62(suppl 5):25-8.
6. United States Pharmacopeial Convention, Inc. USP dispensing information, volume III - approved drug products and legal requirements, 23rd ed. Greenwood Village, CO: Micromedex, 2003.
7. Meyer MC. U. S. Food and Drug Administration requirements for approval of generic drug products. J Clin Psychiatry 2001;62(suppl 5):4-9.
8. Kluznik JC, Walbek NH, Farnsworth MG, Melstrom K. Clinical effects of a randomized switch of patients from Clozaril to generic clozapine. J Clin Psychiatry 2001;62(suppl 5):14-17.
9. Overall JE, Gorham DR. The brief psychiatric rating scale (BPRS): recent developments in ascertainment and scaling. Psychopharmacol Bull 1988;24:97-9.
10. Guy W. Early Clinical Drug Evaluation Unit assessment manual for psychopharmacology, revised. Department of Health, Education, and Welfare publication no. ADM 76-338. Rockville, MD: U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health Psychopharmacology Research Branch, Division of Extramural Research Programs, 1976:218-22.
11. Beck AT, Ward CH, Mendelson, M. An inventory of measuring depression. Arch Gen Psychiatry 1961;4:53-63.
12. Levine J, Schooler NR. SAFTEE: a technique for the systematic assessment of side effects in clinical trials. Psychopharmacol Bull 1986;22:343-81.
13. Novartis Pharmaceuticals Corporation. Clozaril (clozapine) package insert. East Hanover, NJ; September 1999.
14. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45(9):789-96.